But now, after re-examining the drug at the request of Eli Lilly, the medicines committee has recommended granting Kisunla ...

Four months after giving Eli Lilly’s Alzheimer’s disease treatment a thumbs-down, Europe’s Committee for Medicinal Products ...

Morning. Today, we discuss how Duchenne patients and their families are responding to the shelving of Sarepta Therapeutics’ ...

Eli Lilly's donanemab gets CHMP backing for early Alzheimer's in select patients after trials show reduced disease ...

Eli Lilly said on Friday that the European Medicines Agency (EMA) has recommended approval of its drug Kisunla for certain ...

Eli Lilly has cleared a major hurdle in its bid to win European approval for its Alzheimer's disease drug Kisunla.